0 231

Cited 0 times in

Targeted therapies and checkpoint inhibitors in sarcoma

Authors
 M Vasella  ;  E Gousopoulos  ;  M Guidi  ;  G Storti  ;  S Y Song  ;  G Grieb  ;  C Pauli  ;  N Lindenblatt  ;  P Giovanoli  ;  B-S Kim 
Citation
 QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, Vol.115(12) : 793-805, 2022-12 
Journal Title
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
ISSN
 1460-2725 
Issue Date
2022-12
MeSH
Humans ; Immune Checkpoint Inhibitors / therapeutic use ; Immunotherapy / methods ; Liposarcoma* Sarcoma* / drug therapy
Abstract
Sarcomas are defined as a group of mesenchymal malignancies with over 100 heterogeneous subtypes. As a rare and difficult to diagnose entity, micrometastasis is already present at the time of diagnosis in many cases. Current treatment practice of sarcomas consists mainly of surgery, (neo)adjuvant chemo- and/or radiotherapy. Although the past decade has shown that particular genetic abnormalities can promote the development of sarcomas, such as translocations, gain-of-function mutations, amplifications or tumor suppressor gene losses, these insights have not led to established alternative treatment strategies so far. Novel therapeutic concepts with immunotherapy at its forefront have experienced some remarkable success in different solid tumors while their impact in sarcoma remains limited. In this review, the most common immunotherapy strategies in sarcomas, such as immune checkpoint inhibitors, targeted therapy and cytokine therapy are concisely discussed. The programmed cell death (PD)-1/PD-1L axis and apoptosis-inducing cytokines, such as TNF-related apoptosis-inducing ligand (TRAIL), have not yielded the same success like in other solid tumors. However, in certain sarcoma subtypes, e.g. liposarcoma or undifferentiated pleomorphic sarcoma, encouraging results in some cases when employing immune checkpoint inhibitors in combination with other treatment options were found. Moreover, newer strategies such as the targeted therapy against the ancient cytokine macrophage migration inhibitory factor (MIF) may represent an interesting approach worth investigation in the future.
Full Text
https://academic.oup.com/qjmed/article/115/12/793/6118237
DOI
10.1093/qjmed/hcab014
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Plastic and Reconstructive Surgery (성형외과학교실) > 1. Journal Papers
Yonsei Authors
Song, Seung Yong(송승용) ORCID logo https://orcid.org/0000-0002-3145-7463
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194836
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links